Emergent BioSolutions
400 Professional Drive
Suite 400
Gaithersburg
Maryland
20879
United States
Tel: 240-631-3200
Fax: 240-631-3203
Website: https://www.emergentbiosolutions.com/
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter.
Stock Symbol: EBS
575 articles about Emergent BioSolutions
-
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
4/22/2024
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024. Conference Call Information Participants can access the conference call live via webcast.
-
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
3/28/2024
Emergent BioSolutions Inc. remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN® Nasal Spray to help save lives in opioid overdose emergencies.
-
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
3/25/2024
Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility.
-
Despite the changing landscape in biopharma, many companies are still recruiting. If you’re looking to make a career change, here are 12 biopharma companies hiring on BioSpace now.
-
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
3/6/2024
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023.
-
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
2/29/2024
Emergent BioSolutions Inc. will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023.
-
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
2/21/2024
Emergent BioSolutions Inc. today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024.
-
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
1/11/2024
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax ® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease.
-
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
1/9/2024
Emergent BioSolutions today announced that Haywood Miller, Interim Chief Executive Officer and Rich Lindahl, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PT.
-
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
11/28/2023
Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services has awarded a $75 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of newly licensed anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted).
-
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
11/24/2023
Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.
-
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
11/8/2023
Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023.
-
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
10/30/2023
Emergent BioSolutions Inc. has rescheduled its conference call to Wednesday, November 8, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023.
-
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
10/19/2023
Emergent BioSolutions Inc. will host a conference call on Thursday, November 2, 2023, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023.
-
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
8/30/2023
Emergent BioSolutions Inc. announced NARCAN® Naloxone HCl Nasal Spray 4 mg will be available on shelves nationwide and online beginning in September.
-
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
8/8/2023
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2023. It also announced strategic steps to reduce investment in and de-emphasize focus on growth in its CDMO business.
-
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
8/8/2023
Emergent BioSolutions (NYSE: EBS) today announced it is reducing investment in and de-emphasizing focus on growth in its CDMO services business.
-
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
7/31/2023
Emergent BioSolutions Inc. announced that it was awarded a 10-year contract by the BARDA, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, valued at up to a maximum of $704 million, for advanced development, manufacturing scale-up, and procurement of Ebanga™, a licensed treatment for Ebola virus disease.
-
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
7/25/2023
Emergent BioSolutions Inc. will host a conference call on Tuesday, August 8, 2023, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2023, recent business developments, revenue guidance for the third quarter of 2023, and financial outlook for full year 2023.
-
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
7/20/2023
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.